The REMS Double Down: Two Indications, Two REMS For Ovation’s Sabril?

If FDA follows an advisory committee's advice to approve Ovation's Sabril (vigabatrin) for two separate epilepsy indications, it may require a first for the REMS era: two Risk Evaluation and Mitigation Strategies for a single product